Quantum BioPharma is trading at $2.65, up 10.42% in pre-market, with biotech-sector strength the likeliest explanation for the move.
- No fresh company-specific catalyst has been confirmed.
- FDA clearance to advance Lucid-MS into Phase 2 was announced October 20, not overnight news for October 22; summit-attendance coverage dates to September 15.
- Broad-market indices are lower, so the move is not clearly tracking the wider market.